Department of Urology, Selcuk University Meram Medical Faculty, Konya, Turkey.
Int Urol Nephrol. 2010 Sep;42(3):647-55. doi: 10.1007/s11255-009-9641-y. Epub 2009 Sep 30.
Renal ischemia/reperfusion (I/R) which is an important cause of renal dysfunction is inevitable in renal transplantation, surgical revascularization of the renal artery, partial nephrectomy and treatment of suprarenal aortic aneurysms.
The purpose of this study was to investigate the efficacy of α-tocopherol and erdosteine combination in the reduction in injury induced by ROS in a rat model of renal ischemia-reperfusion.
Thirty-six- male Wistar albino rats weighing 200-250 g were utilized for this study. Rats were divided into six groups, and each group was consistent of six rats: (1) sham-operated (control), (2) ischemia group (3) I/R group, (4) I/R/α-tocoferol group (5) I/erdosteine group (6). I/R/α-tocoferol and erdosteine group. Biochemically tissue MDA, XO and SOD activities, light and electron microscopic findings were evaluated.
The erdosteine and α-tocoferol significantly reversed the effect of protein oxidation and lipid peroxidation induced by I/R shown by the decreased levels of MDA and XO activities. Both MDA and XO levels were found to be lower in group 6 compared to single agent treatment groups, and this was significantly different. All treatment groups showed increased SOD activity, which accounts for their oxidative properties. The mean Paller score of the combination treatment group (group 6) was lower than all groups except the sham group (3.67 ± 1.2), and this finding was statistically significant (0.05). Our results showed that the antioxidant pretreatment with α-tocopherol and erdosteine combination reduced lipid peroxidation of renal cellular membranes in a model of normothermic renal ischemia-reperfusion in rats. Combination of erdosteine and α-tocopherol has a synergistic effect of protection against oxidative processes. Long-term use of α-tocopherol seems to have a greater effect on the prevention of IR injury. However, further investigations are needed for the clinical applications of our findings.
肾缺血/再灌注(I/R)是肾功能障碍的一个重要原因,在肾移植、肾动脉血管重建术、部分肾切除术和治疗肾上腹主动脉瘤时不可避免会发生。
本研究旨在探讨α-生育酚和厄多司坦联合应用对肾缺血再灌注大鼠模型中 ROS 诱导损伤的疗效。
本研究使用了 36 只雄性 Wistar 白化大鼠,体重 200-250g。将大鼠分为 6 组,每组 6 只:(1)假手术(对照)组,(2)缺血组,(3)I/R 组,(4)I/R/α-生育酚组,(5)I/厄多司坦组,(6)I/R/α-生育酚和厄多司坦组。评估了组织 MDA、XO 和 SOD 活性的生化变化,以及光镜和电镜下的观察结果。
厄多司坦和α-生育酚显著逆转了 I/R 引起的蛋白质氧化和脂质过氧化作用,表现为 MDA 和 XO 活性降低。与单药治疗组相比,第 6 组的 MDA 和 XO 水平均较低,差异有统计学意义(P<0.05)。所有治疗组的 SOD 活性均升高,这表明它们具有抗氧化特性。联合治疗组(第 6 组)的平均 Pallér 评分低于除假手术组(3.67±1.2)以外的所有组,差异有统计学意义(P<0.05)。我们的结果表明,在大鼠常温肾缺血再灌注模型中,α-生育酚和厄多司坦联合应用的抗氧化预处理可降低肾细胞膜的脂质过氧化。厄多司坦和α-生育酚联合具有协同的抗氧化作用。长期使用α-生育酚似乎对预防 IR 损伤有更大的作用。然而,我们的研究结果需要进一步的临床应用研究。